Drug Trial Radar · NCT07283835
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Dec 4, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Lepu Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and safety of Cretostimogene in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without Ta/T1 papillary tumors.
Conditions
- Non Muscle Invasive Bladder Cancer
- High-grade Ta/ T1 Papillary Disease Bladder Cancer
Interventions
Cretostimogene GrenadenorepvecBiological
Engineered Oncolytic Adenovirus
n-dodecyl-B-D-maltosideOther
Transduction-enhancing agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete response rate at any time in BCG-unresponsive high-risk NMIBC with or without Ta/T1 papillary tumors including CISTime frame: 36 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital (First Clinical Medical School of Peking University)
Beijing, Beijing Municipality, China · Recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
The Affiliated Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Recruiting
The Second Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.